Abound Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$103K Sell
1,791
-351
-16% -$20.2K 0.02% 157
2026
Q1
$130K Buy
2,142
+153
+8% +$8.92K 0.03% 124
2025
Q4
$107K Buy
1,989
+16
+0.8% +$770 0.03% 133
2025
Q3
$89K Buy
1,973
+144
+8% +$6.72K 0.02% 148
2025
Q2
$84.7K Buy
1,829
+1,524
+500% +$74.8K 0.02% 145
2025
Q1
$18.6K Sell
305
-205
-40% -$11.9K 0.01% 302
2024
Q4
$28.8K Buy
510
+115
+29% +$6.42K 0.01% 228
2024
Q3
$20.4K Buy
395
+32
+9% +$1.5K 0.01% 293
2024
Q2
$15.1K Sell
363
-43
-11% -$1.92K 0.01% 303
2024
Q1
$22K Sell
406
-287
-41% -$14.6K 0.01% 231
2023
Q4
$35.6K Buy
693
+243
+54% +$12.8K 0.01% 178
2023
Q3
$26.1K Sell
450
-92
-17% -$5.64K 0.01% 188
2023
Q2
$34.7K Buy
542
+90
+20% +$6.04K 0.01% 164
2023
Q1
$31.3K Sell
452
-82
-15% -$5.78K 0.01% 164
2022
Q4
$38.4K Sell
534
-57
-10% -$4.3K 0.02% 135
2022
Q3
$42K Buy
+591
New +$42.9K 0.02% 128

Other funds holding BMY

Abound Wealth Management's BMY Position: Q2 2026 in Review

Abound Wealth Management reduced its Bristol-Myers Squibb (BMY) stake by 16% in Q2 2026, selling an estimated $20.2K and leaving 1,791 shares worth $103K. The position accounts for 0.02% of the portfolio, ranked #157.

Abound Wealth Management first reported a position in BMY in Q3 2022 and has held it in 16 quarters since. The position peaked at $130K in Q1 2026. 799 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Abound Wealth Management held 1,791 shares of Bristol-Myers Squibb worth $103K as of Q2 2026.
  • Abound Wealth Management sold 351 Bristol-Myers Squibb shares in Q2 2026, an estimated $20.2K.
  • Bristol-Myers Squibb made up 0.02% of Abound Wealth Management's portfolio in Q2 2026, its #157 holding.
  • Abound Wealth Management first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Bristol-Myers Squibb position peaked at $130K in Q1 2026.
  • 799 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.